Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Immunocore Holdings (IMCR) Stock Price & Analysis
135 Followers
IMCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.05 - $76.98
Previous Close$36.43
Volume345.07K
Average Volume (3M)794.10K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)£332.54M
Total Debt (Recent Filing)£69.30M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 07, 2024EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,088,346
10 Day Avg. Volume989,840
30 Day Avg. Volume794,102
Standard Deviation0.15
R-Squared0.08
Alpha0.00326
Financial Highlights & Ratios
Price to Book (P/B)8.07
Price to Sales (P/S)12.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio404.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$86.90Price Target Upside149.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Immunocore Holdings News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsPromising clinical activity data in lead PRAME bispecific program in cutaneous melanoma support advancement to Phase 3 program in a frontline treatment setting.
Financial OpportunitiesThe sell-off in IMCR shares, down approximately 10%, is considered overdone and has provided attractive entry point opportunities for investors.
Safety ProfileBrenetafusp demonstrated a favorable safety profile in combination with CPI, which bodes well for the Phase 3 program evaluating brenetafusp plus CPI as frontline treatment in advanced cutaneous melanoma.
Bears Say
Clinical DataThe overall response rate (ORR) in the full presentation was reported to be 11% with a 56% disease control rate (DCR), compared to a 13% ORR and 61% DCR from the ASCO abstract.
Competitor PerformanceCompetitor data appears to be stronger. Immatics released updated data from its PRAME TCR therapy showing a confirmed ORR of 55% and a DCR of 90%.
Market ReactionIMCR shares trading down ~12% in post-market trading on negative market reaction to highly anticipated initial Phase 1 data for IMCR's PRAME-targeting bispecific asset.
---
Ownership Overview
0.04% Insiders
21.28% Mutual Funds
1.04% Other Institutional Investors
77.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $33.05 and its highest was $76.98 in the past 12 months.
What is Immunocore Holdings’s market cap?
Currently, no data Available
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on May 08, 2024. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.368 by -$0.122.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -$0.47.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 48,791,546 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.368. Following the earnings report the stock price went up 0.459%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Among the largest hedge funds holding Immunocore Holdings’s share is Baker Bros Advisors LP. It holds Immunocore Holdings’s shares valued at 98M.
---
Immunocore Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.90 (149.71% Upside)
$86.90 (149.71% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 777.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.24%
12-Months-Change
Fundamentals
Return on Equity
-17.05%
Trailing 12-Months
Asset Growth
86.72%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
---
IMCR Company Deck
---
IMCR Earnings Call
Q4 2024
0:00 / 0:00
---
IMCR Stock 12 Month Forecast
Average Price Target
$86.90
▲(149.71% Upside)
Technical Analysis
Best Analysts Covering IMCR
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+14.40%
reiterated a buy rating 4 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +14.40% per trade.
---